Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Wynn Resorts, Limited — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Wynn Resorts, Limited trades at $75.15 (market cap $7.75B). The key difference: Halozyme Therapeutics Inc. Common Stock is the larger of the two by market cap, and Wynn Resorts, Limited pays a 1.33% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Wynn Resorts, Limited for 76 Days on average.
| HALO | WYNN | |
|---|---|---|
Market Cap | $12.58B | $7.75B |
Volume | 2,179,278 | 2,243,813 |
Sector | Health | Consumer Cyclical |
52-Week High | $115.22 | $133.09 |
52-Week Low | $61.63 | $74.97 |
Typical Hold Time | 1 Days | 76 Days |
Enterprise Value | $14.49B | $17.99B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wynn Resorts trades at $75.29, up 0.43% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported Q2 2026 EPS of $1.24, beating expectations, driven by Macau strength, but faces margin pressure in the U.S. and rising capital expenditure for new projects. Revenue for 2025 was $7.14 billion with a net income margin of 4.58%, while the balance sheet shows high long-term debt of $10.50 billion and negative shareholder equity.
The outlook is mixed: analyst consensus is bullish with a $132.36 price target, but risks include high leverage, project costs, and competitive pressures. Upside hinges on Macau recovery and successful project execution, while downside risks stem from debt servicing and macroeconomic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
